View Item 

Show simple item record

Current prescription of prophylactic factor infusions and perceived adherence for children and adolescents with haemophilia: a survey of haemophilia healthcare professionals in the United States
dc.contributor.authorThornburg, C. D.en_US
dc.contributor.authorCarpenter, S.en_US
dc.contributor.authorZappa, S.en_US
dc.contributor.authorMunn, J.en_US
dc.contributor.authorLeissinger, C.en_US
dc.date.accessioned2012-07-12T17:24:10Z
dc.date.available2013-09-03T15:38:27Zen_US
dc.date.issued2012-07en_US
dc.identifier.citationThornburg, C. D. ; Carpenter, S. ; Zappa, S. ; Munn, J. ; Leissinger, C. (2012). "Current prescription of prophylactic factor infusions and perceived adherence for children and adolescents with haemophilia: a survey of haemophilia healthcare professionals in the United States." Haemophilia 18(4). <http://hdl.handle.net/2027.42/92069>en_US
dc.identifier.issn1351-8216en_US
dc.identifier.issn1365-2516en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/92069
dc.publisherWiley Periodicals, Inc.en_US
dc.publisherBlackwell Publishing Ltden_US
dc.subject.otherTreatment Adherenceen_US
dc.subject.otherHaemarthrosisen_US
dc.subject.otherHaemophiliaen_US
dc.subject.otherProphylactic Treatmenten_US
dc.titleCurrent prescription of prophylactic factor infusions and perceived adherence for children and adolescents with haemophilia: a survey of haemophilia healthcare professionals in the United Statesen_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelOncology and Hematologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumDepartment of Pediatrics, University of Michigan Medical Center, Ann Arbor, MIen_US
dc.contributor.affiliationotherDepartment of Medicine, Tulane University, New Orleans, LA, USAen_US
dc.contributor.affiliationotherCook Children’s Medical Center, Forth Worth, TXen_US
dc.contributor.affiliationotherDepartment of Pediatrics, Children’s Mercy Hospital, Kansas City, MO; Department of Pediatricsen_US
dc.contributor.affiliationotherDepartment of Pediatrics, Duke University Medical Center, Durham, NCen_US
dc.identifier.pmid22335526en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/92069/1/hae2756_sm_DataS1.pdf
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/92069/2/hae2756.pdf
dc.identifier.doi10.1111/j.1365-2516.2012.02756.xen_US
dc.identifier.sourceHaemophiliaen_US
dc.identifier.citedreferenceDuncan N, Kronenberger W, Roberson C, Shapiro A. VERITAS‐Pro: a new measure of adherence to prophylactic regimens in haemophilia. Haemophilia 2010; 16: 247 – 55.en_US
dc.identifier.citedreferenceButler RB, McClure W, Wulff K. Practice patterns in haemophilia A therapy – a survey of treatment centres in the United States. Haemophilia 2003; 9: 549 – 54.en_US
dc.identifier.citedreferenceKisker CT, Eisberg A, Schwartz B. Prophylaxis in factor IX deficiency product and patient variation. Haemophilia 2003; 9: 279 – 84.en_US
dc.identifier.citedreferenceNilsson I, Berntorp E, Lofqvist T, Pettersson H. Twenty‐five years’ experience of prophylactic treatment in severe haemophilia A and B. J Int Med 1992; 232: 25 – 32.en_US
dc.identifier.citedreferencePanicker J, Warrier I, Thomas R, Lusher JM. The overall effectiveness of prophylaxis in severe haemophilia. Haemophilia 2003; 9: 272 – 8.en_US
dc.identifier.citedreferenceFischer K, van der Bom JG, Molho P et al. Prophylactic versus on‐demand treatment strategies for severe haemophilia: a comparison of costs and long‐term outcome. Haemophilia 2002; 8: 745 – 52.en_US
dc.identifier.citedreferencevan den Berg HM, Fischer K, van der Bom JG. Comparing outcomes of different treatment regimens for severe haemophilia. Haemophilia 2003; 9 ( Suppl 1 ): 27 – 31.en_US
dc.identifier.citedreferenceFischer K, Van Den Berg M. Prophylaxis for severe haemophilia: clinical and economical issues. Haemophilia 2003; 9: 376 – 81.en_US
dc.identifier.citedreferenceManco‐Johnson MJ, Abshire TC, Shapiro AD et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 2007; 357: 535 – 44.en_US
dc.identifier.citedreferenceGringeri A, Lundin B, Mackensen SV, Mantovani L, Mannucci PM. A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study). J Thromb Haemost 2011; 9: 700 – 10.en_US
dc.identifier.citedreferenceThornburg CD. Physicians’ perceptions of adherence to prophylactic clotting factor infusions. Haemophilia 2008; 14: 25 – 9.en_US
dc.identifier.citedreferenceBosworth H. Medication treatment adherence. In: Bosworth H, Oddone E, Weinberger M eds. Patient Treatment Adherence: Concepts, Interventions, and Measurement. Mahweh: Lawrence Erlbaum Associates, Publishers, 2006: 158.en_US
dc.identifier.citedreferenceHaynes RB, Sackett DL, Gibson ES et al. Improvement of medication compliance in uncontrolled hypertension. Lancet 1976; 1: 1265 – 8.en_US
dc.identifier.citedreferencePsaty BM, Koepsell TD, Wagner EH, LoGerfo JP, Inui TS. The relative risk of incident coronary heart disease associated with recently stopping the use of beta‐blockers. JAMA 1990; 263: 1653 – 7.en_US
dc.identifier.citedreferenceOsterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005; 353: 487 – 97.en_US
dc.identifier.citedreferenceCenters for Disease Control and Prevention (CDC) HTC staff database. Available at http://www2a.cdc.gov/ncbddd/htcweb/udc_report/udc_report.asp. Accessed 2010.en_US
dc.identifier.citedreferenceFeldman BM, Pai M, Rivard GE et al. Tailored prophylaxis in severe hemophilia A: interim results from the first 5 years of the Canadian Hemophilia Primary Prophylaxis Study. J Thromb Haemost 2006; 4: 1228 – 36.en_US
dc.identifier.citedreferenceKurnik K, Bidlingmaier C, Engl W, Chehadeh H, Reipert B, Auerswald G. New early prophylaxis regimen that avoids immunological danger signals can reduce FVIII inhibitor development. Haemophilia 2010; 16: 256 – 62.en_US
dc.identifier.citedreferenceUniversal Data Collection Project. Available at https://www2a.cdc.gov/ncbddd/htcweb/Main.asp. Accessed 2002, 2006 and 2010.en_US
dc.identifier.citedreferenceChan AK, Decker K, Warner M. Adherence with haemophilia treatments: a survey of haemophilia healthcare professionals in Canada. Haemophilia 2011; 17: 816 – 7.en_US
dc.identifier.citedreferenceFischer K, Valentino L, Ljung R, Blanchette V. Prophylaxis for severe haemophilia: clinical challenges in the absence as well as in the presence of inhibitors. Haemophilia 2008; 14 ( Suppl 3 ): 196 – 201.en_US
dc.identifier.citedreferenceLindvall K, Colstrup L, Wollter IM et al. Compliance with treatment and understanding of own disease in patients with severe and moderate haemophilia. Haemophilia 2006; 12: 47 – 51.en_US
dc.identifier.citedreferenceRichards M, Altisent C, Batorova A et al. Should prophylaxis be used in adolescent and adult patients with severe haemophilia? An European survey of practice and outcome data. Haemophilia 2007; 13: 473 – 9.en_US
dc.identifier.citedreferenceWalsh CE, Valentino LA. Factor VIII prophylaxis for adult patients with severe haemophilia A: results of a US survey of attitudes and practices. Haemophilia 2009; 15: 1014 – 21.en_US
dc.identifier.citedreferenceBosworth HB, Granger BB, Mendys P et al. Medication adherence: a call for action. Am Heart J 2011; 162: 412 – 24.en_US
dc.identifier.citedreferencedu Treil S, Rice J, Leissinger CA. Quantifying adherence to treatment and its relationship to quality of life in a well‐characterized haemophilia population. Haemophilia 2007; 13: 493 – 501.en_US
dc.identifier.citedreferenceRagni MV, Fogarty PJ, Josephson NC, Neff AT, Raffini LJ, Kessler CM. Survey of current prophylaxis practices and bleeding characteristics of children with severe haemophilia A in US haemophilia treatment centres. Haemophilia 2012; 18: 63 – 8.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
hae2756_sm_DataS1.pdf
Size:
101.3KB
Format:
PDF
View/Open
Name:
hae2756.pdf
Size:
131.8KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.